The pharmaceutical landscape is currently undergoing a seismic regulatory shift. With the 2025 joint announcement by the FDA and EMA initiating a phased withdrawal of mandatory animal testing, the race is on for validated,
human-relevant in vitro models. Traditional drug development has long been plagued by exorbitant costs and low success rates due to the physiological discrepancy between animal experiments and human biology.
To address these challenges, ORGANOIDSCIENCES has developed the ODISEI (Organoid-based Discovery platform for Innovative Screening, Evaluation, and Identification) platform—a transformative suite of tools designed to simulate complex human biological interactions with unprecedented accuracy.
The ODISEI platform integrates human organoids with advanced co-culture systems and analytical workflows to provide a credible alternative to conventional 2D assays and animal models.
1 ORGANOIDSCIENCES Ltd., Republic of Korea
2 COSMAX BTI, Republic of Korea
3 Lambda Biologics GmbH, Germany
4 Corresponding Author
Download the full poster “Innovations in Translational Research: Organoids as Versatile Tools for Therapeutic Development”
To access the full copy of this resource, kindly fill in the following information
